Sertraline Hydrochloride Tablet
Product Images NDC 50090-7694

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sertraline Hydrochloride (NDC 50090-7694). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907694)

FDA Label Image

Image Description (Struct)

FDA Label Image

Table 3 (Table 3)

This is a summary of common adverse reactions in adults with MDD, OCD, PD, PTSD, SAD, and PMDD from pooled placebo-controlled trials comparing Sertraline hydrochloride to placebo. Side effects such as palpitations, visual impairment, nausea, diarrhea, constipation, fatigue, decreased appetite, dizziness, somnolence, insomnia, agitation, and decreased libido were reported more frequently in Sertraline hydrochloride-treated patients than in those receiving a placebo. Male sexual dysfunction and skin-related issues like hyperhidrosis were also documented.*

FDA Label Image

Table1 (Table1)

This text provides information about the recommended daily dosage of sertraline hydrochloride for patients with major depressive disorder (MDD), obsessive-compulsive disorder (OCD), panic disorder (PD), post-traumatic stress disorder (PTSD), and social anxiety disorder (SAD). The starting dose for adults with MDD is 50mg, while for OCD it ranges from 50-200 mg. The therapeutic range for PD, PTSD, and SAD in adults is not specified. For pediatric patients with OCD, the dosage ranges from 50-200 mg depending on the specific age group.*

FDA Label Image

Table2 (Table2)

This table provides insights into the risk differences of the number of cases of suicidal thoughts or behaviors in placebo-controlled trials of antidepressants in pediatric and adult patients. It categorizes the age range and shows the differences in the number of patients with suicidal thoughts or behaviors per 1000 patients treated compared to placebo. The data indicates an increase in suicidal thoughts or behaviors in pediatric patients and a decrease in adult patients across different age ranges.*

FDA Label Image

Image Description (Table4)

This excerpt provides information about the most common sexual adverse reactions in adults with various conditions like major depressive disorder, obsessive-compulsive disorder, and others, who were involved in controlled trials with sertraline hydrochloride. The data presented in Table 4 reveals sexual adverse reactions experienced by men and women in comparison to placebo, with items such as ejaculation failure, libido decrease, erectile dysfunction, ejaculation disorder, and male sexual dysfunction appearing in men and libido decrease in women.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.